Basic experiments have shown that Sev can inhibit cell viability in a dose-dependent manner in U87 and U251 glioma cells, increase ROS levels and Fe2+ concentrations, upregulate the expression of transferrin, ferritin, and Beclin-1, and induce glial tumour cell death. The gene discussed is BECN1; the disease is glioma.